68Ga-TP1580 as a novel molecular probe for HER2-positive tumor imaging using MicroPET

被引:0
|
作者
Zhong, Jinxiu [1 ]
Pan, Donghui [2 ]
Guan, Yan-xing [3 ]
机构
[1] Nanchang Univ, Jiangxi Canc Hosp, Nanchang 330006, Jiangxi, Peoples R China
[2] Jiangsu Inst Nucl Med, Key Lab Nucl Med, Wuxi 210463, Jiangsu, Peoples R China
[3] Nanchang Univ, Affiliated Hosp 1, Dept Nucl Med Radiol, Nanchang 330006, Jiangxi, Peoples R China
关键词
HER2; MicroPET; Imaging; Peptides; BREAST-CANCER; CLINICAL-APPLICATIONS; HER2; EXPRESSION; PET; RECEPTOR; ANTAGONISTS; PEPTIDES; TOMOGRAPHY; CARCINOMAS; THERAPY;
D O I
10.1007/s10967-022-08236-x
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
HER2 is an attractive target for the treatment of breast cancer. Tc-99(m)-labeled HER2-specific binding to the small molecule mimetic peptide B2-S22-AFA shows the potential of detecting HER2 expression in vivo (Zhang in Transl Oncol 10:518-526, 2017). However, the low resolution of SPECT-CT imaging and the inability to quantitatively analyze may partially limit its wide use.Ga-68 is an excellent PET radionuclide due to availability, nearly quantitative reaction, and short physical half-life. In this study, Ga-68-labeled-NOTA- B2-S22-AFA (hereinafter referred to as Ga-68-TP1580) was applied for PET-CT imaging in HER2 breast cancer xenografts mice. In vitro studies and MicroPET imaging were performed in the SKBR-3 breast cancer model. Ga-68-TP1580 could be produced within 20 min with 93.2 +/- 2.1% yield and the radiochemical purity was greater than 95%. The tracer was stable in PBS and human serum for at least 2 h. MicroPET imaging revealed that the SKBR-3 xenografts were visualized and the tumor uptakes were 1.22 +/- 0.04, 0.71 +/- 0.07, and 0.43 +/- 0.04% ID/g at 0.5 h, 1 h, and 2 h.The corresponding tumor-to-blood and tumor-to-muscle ratios were 1.05 +/- 0.06, 1.34 +/- 0.21, and 1.33 +/- 0.57, respectively, and 4.02 +/- 1.39, 7.47 +/- 2.86, and 5.82 +/- 1.98 at 0.5 h, 1 h, and 2 h. No significant decrease in tumor uptake of Ga-68-TP1580 was seen after injection of excess unlabeled TP1580.In conclusion, TP1580 can be labeled by Ga-68 with high radiochemical purity (> 95%), good vitro stability (keep consistent radiochemical purity > 95% for more than 2 h).Ga-68-TP1580 can combine with target tissue and show some tumor uptake in SKBR-3 xenografts, but not be blocked by NOTA-B2-S22-AFA which indicates poor specificity.
引用
收藏
页码:1531 / 1543
页数:13
相关论文
共 50 条
  • [41] Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
    Lisa Grüntkemeier
    Aditi Khurana
    Farideh Zamaniyan Bischoff
    Oliver Hoffmann
    Rainer Kimmig
    Mathew Moore
    Philip Cotter
    Sabine Kasimir-Bauer
    Breast Cancer, 2022, 29 : 487 - 497
  • [42] Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™-HER2-FISH workflow
    Gruentkemeier, Lisa
    Khurana, Aditi
    Bischoff, Farideh Zamaniyan
    Hoffmann, Oliver
    Kimmig, Rainer
    Moore, Mathew
    Cotter, Philip
    Kasimir-Bauer, Sabine
    BREAST CANCER, 2022, 29 (03) : 487 - 497
  • [43] Discovery of Hapten-Specific scFv from a Phage Display Library and Applications for HER2-Positive Tumor Imaging
    Kim, Hye-Yeong
    Wang, Xiaolei
    Wahlberg, Brendon
    Edwards, W. Barry
    BIOCONJUGATE CHEMISTRY, 2014, 25 (07) : 1311 - 1322
  • [44] Bovine serum albumin encapsulation of near infrared fluorescent nano-probe with low nonspecificity and cytotoxicity for imaging of HER2-positive breast cancer cells
    Wei, Tianxiang
    Xing, Hong
    Wang, Huafeng
    Zhang, Yuluan
    Wang, Junning
    Shen, Jian
    Dai, Zhihui
    TALANTA, 2020, 210
  • [45] Molecular imaging of fibroblast activation protein after myocardial infarction using the novel radiotracer [68Ga]MHLL1
    Langer, Laura B. N.
    Hess, Annika
    Korkmaz, Zekiye
    Tillmanns, Jochen
    Reffert, Laura M.
    Bankstahl, Jens P.
    Bengel, Frank M.
    Thackeray, James T.
    Ross, Tobias L.
    THERANOSTICS, 2021, 11 (16): : 7755 - 7766
  • [46] Ex vivo dual gene therapy using human adipocytes secreting anti-HER2 antibody on HER2-positive xenograft tumor models
    Ryotaro Teranaka
    Hiroshi Fujimoto
    Takahito Masuda
    Masayuki Kuroda
    Yasuyuki Aoyagi
    Takeshi Nagashima
    Mamoru Takada
    Junta Sakakibara
    Hideyuki Yamada
    Hiroto Yamamoto
    Yoshitaka Kubota
    Masayuki Ohtsuka
    Breast Cancer, 2023, 30 : 1018 - 1027
  • [47] Ex vivo dual gene therapy using human adipocytes secreting anti-HER2 antibody on HER2-positive xenograft tumor models
    Teranaka, Ryotaro
    Fujimoto, Hiroshi
    Masuda, Takahito
    Kuroda, Masayuki
    Aoyagi, Yasuyuki
    Nagashima, Takeshi
    Takada, Mamoru
    Sakakibara, Junta
    Yamada, Hideyuki
    Yamamoto, Hiroto
    Kubota, Yoshitaka
    Ohtsuka, Masayuki
    BREAST CANCER, 2023, 30 (06) : 1018 - 1027
  • [48] Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6
    von Witting, Emma
    Garousi, Javad
    Lindbo, Sarah
    Vorobyeva, Anzhelika
    Altai, Mohamed
    Oroujeni, Maryam
    Mitran, Bogdan
    Orlova, Anna
    Hober, Sophia
    Tolmachev, Vladimir
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2019, 140 : 109 - 120
  • [49] Anti-HER2 therapy response assessment for guiding treatment (de-)escalation in early HER2-positive breast cancer using a novel deep learning radiomics model
    Tong, Yiwei
    Hu, Zhaoyu
    Wang, Haoyu
    Huang, Jiahui
    Zhan, Ying
    Chai, Weimin
    Deng, Yinhui
    Yuan, Ying
    Shen, Kunwei
    Wang, Yuanyuan
    Chen, Xiaosong
    Yu, Jinhua
    EUROPEAN RADIOLOGY, 2024, 34 (08) : 5477 - 5486
  • [50] Anti-HER2 therapy response assessment for guiding treatment (de-)escalation in early HER2-positive breast cancer using a novel deep learning radiomics model
    Tong, Yiwei
    Hu, Zhaoyu
    Wang, Haoyu
    Huang, Jiahui
    Zhan, Ying
    Chai, Weimin
    Deng, Yinhui
    Yuan, Ying
    Shen, Kunwei
    Wang, Yuanyuan
    Chen, Xiaosong
    Yu, Jinhua
    EUROPEAN RADIOLOGY, 2024, 34 (8) : 5477 - 5486